(Q50853181)
Statements
Natalizumab treatment shows no clinically meaningful effects on immunization responses in patients with relapsing-remitting multiple sclerosis. (English)
1 reference
Michael Kaufman
Howard Rossman
Marianne T Sweetser
Fiona Forrestal
26 March 2014
1 reference